1492 Capital Management LLC Buys 256,139 Shares of Certara, Inc. $CERT

1492 Capital Management LLC lifted its stake in Certara, Inc. (NASDAQ:CERT) by 193.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 388,540 shares of the company’s stock after purchasing an additional 256,139 shares during the period. 1492 Capital Management LLC’s holdings in Certara were worth $3,423,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Osaic Holdings Inc. grew its stake in shares of Certara by 50.7% in the 2nd quarter. Osaic Holdings Inc. now owns 3,491 shares of the company’s stock worth $41,000 after buying an additional 1,175 shares during the last quarter. Corient Private Wealth LLC raised its stake in Certara by 11.7% during the second quarter. Corient Private Wealth LLC now owns 12,362 shares of the company’s stock valued at $144,000 after buying an additional 1,295 shares during the last quarter. Treasurer of the State of North Carolina boosted its holdings in Certara by 2.9% in the second quarter. Treasurer of the State of North Carolina now owns 56,628 shares of the company’s stock worth $663,000 after acquiring an additional 1,597 shares in the last quarter. Nicolet Advisory Services LLC boosted its holdings in Certara by 7.4% in the third quarter. Nicolet Advisory Services LLC now owns 30,608 shares of the company’s stock worth $396,000 after acquiring an additional 2,100 shares in the last quarter. Finally, Mendel Money Management grew its stake in shares of Certara by 1.8% in the third quarter. Mendel Money Management now owns 136,675 shares of the company’s stock worth $1,670,000 after acquiring an additional 2,370 shares during the last quarter. Institutional investors own 73.96% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on CERT. TD Cowen restated a “buy” rating on shares of Certara in a report on Thursday, February 26th. Stephens cut their price objective on shares of Certara from $10.00 to $9.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 12th. KeyCorp reduced their price objective on shares of Certara from $10.00 to $8.00 and set an “overweight” rating for the company in a research note on Monday, April 13th. Morgan Stanley decreased their target price on shares of Certara from $11.00 to $10.00 and set an “equal weight” rating for the company in a report on Tuesday, May 12th. Finally, Wall Street Zen downgraded shares of Certara from a “buy” rating to a “hold” rating in a research note on Sunday, February 15th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Certara currently has an average rating of “Hold” and a consensus price target of $8.85.

Certara Trading Down 0.4%

Shares of NASDAQ:CERT opened at $5.60 on Thursday. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.88 and a quick ratio of 1.88. Certara, Inc. has a 1 year low of $4.45 and a 1 year high of $13.88. The company has a market cap of $871.19 million, a P/E ratio of -56.00 and a beta of 1.49. The stock’s fifty day moving average price is $5.66 and its 200-day moving average price is $7.32.

Certara (NASDAQ:CERT) last released its quarterly earnings data on Monday, May 11th. The company reported $0.09 EPS for the quarter, missing the consensus estimate of $0.11 by ($0.02). Certara had a positive return on equity of 3.52% and a negative net margin of 3.60%.The business had revenue of $106.92 million during the quarter, compared to the consensus estimate of $106.13 million. During the same quarter in the previous year, the business posted $0.14 earnings per share. Certara’s quarterly revenue was up .8% compared to the same quarter last year. Certara has set its FY 2026 guidance at 0.350-0.410 EPS. Sell-side analysts expect that Certara, Inc. will post 0.24 earnings per share for the current year.

Certara Company Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.